Abbott Raises 2026 Profit Forecast After Medical Devices Sales Jump 9% to $5.85 Billion

The Quick Take

• Abbott Laboratories raised its full-year 2026 profit forecast after medical devices segment quarterly sales grew 9% to $5.85 billion
• Strength in both diagnostics and heart devices drove the revenue beat and the upward guidance revision
• The result positions Abbott as a clear beneficiary of sustained global healthcare spending on diagnostic and cardiac care devices

Abbott Laboratories' decision to raise its 2026 profit forecast reflects the sustained strength in medical device demand that has characterized the post-pandemic healthcare recovery. The 9% quarterly growth in medical devices — reaching $5.85 billion — signals that hospital capital spending and elective procedure volumes are recovering at a pace that supports premium medical technology pricing. Diagnostics strength is particularly notable: Abbott's diagnostics franchise was a COVID-era windfall that many analysts had expected to normalize sharply downward. Instead, the segment is finding durable demand from continuous glucose monitoring growth, infectious disease testing, and point-of-care diagnostics adoption in emerging markets globally.

Abbott's guidance raise directly benefits sector peers including Medtronic, Boston Scientific, and Edwards Lifesciences by lifting the sector's consensus valuation floor. When the largest diversified medtech company raises guidance, it signals that hospital procurement cycles are healthy and reimbursement trends are supportive — conditions that positively affect all device makers. This result may increase investor expectations for upcoming peer earnings, making any miss more sharply punishing. Healthcare REITs and hospital operators may also see positive read-through sentiment as strong medtech demand implies healthy procedure volumes and high hospital utilization rates across the broader US healthcare system.

Watch Abbott's next quarterly earnings for whether the 9% medical device growth rate is sustainable or represents a pull-forward in hospital procurement cycles. Any commentary on continuous glucose monitoring pricing trends — where Dexcom competes directly — will reveal share gain or loss dynamics. The macro variable is US healthcare reimbursement policy: any Medicare or Medicaid payment rate changes for cardiac devices or diagnostic tests would directly impact Abbott's guidance trajectory. International commentary on India and Asian emerging market diagnostics adoption — still significantly underpenetrated — will indicate whether Abbott's longer-term growth runway is developing as expected.

Synthesized from 1 source.